IGF2BP1 could attenuate the tumor suppressive effect of cisplatin and induce cisplatin resistance in ovarian cancer, oral squamous cell carcinoma, seminoma, and endometrial cancer cells by regulating its target mRNA stabilization. This evidence concerns the gene IGF2BP1 and neoplasm.